[144] United Therapeutics Corp SEC Filing

Rhea-AI Filing Summary

United Therapeutics Corp. (UTHR) has received a Form 144 filing indicating a planned sale of 11,000 common shares through Morgan Stanley Smith Barney on or after 07/10/2025. The proposed transaction is valued at $3.30 million, based on the filing’s quoted market value. The company has 45.11 million shares outstanding, so the contemplated sale represents roughly 0.024 % of total shares.

The filer, identified as Paul Mahon, has been an active seller. Over the past three months, the same account reported seven Rule 144 sales totaling 66,000 shares for gross proceeds of about $19.38 million. Individual sale blocks were generally 11,000 shares, executed between 04/17/2025 and 06/26/2025 at prices that generated proceeds of $3.08–$3.31 million per block.

While Rule 144 notices do not guarantee a sale will occur, they provide advance public disclosure of an insider or affiliate’s intent to transact. The filing also certifies that the seller is not in possession of undisclosed material adverse information and, if applicable, is operating under a Rule 10b5-1 plan.

Key take-aways for investors:

• Continuation of a steady liquidation pattern—an additional 11,000 shares planned after 66,000 shares already sold in the prior quarter.
• The cumulative 77,000 shares (0.17 % of shares outstanding) may point to portfolio diversification rather than a large strategic exit.
• No financial performance data or corporate developments are disclosed in the Form 144; the filing is limited to proposed share sales.

Positive

• None.

Negative

• Continued insider selling—a new 11,000-share notice follows 66,000 shares sold in the last three months, potentially dampening investor sentiment.

Insights

Securities Analyst

TL;DR: Small-scale insider sale; signals ongoing divestment, but volume immaterial to float.

The proposed 11,000-share sale equals roughly 0.024 % of UTHR’s outstanding stock, which should have minimal direct market impact. However, the pattern—66,000 shares sold in the prior three months—shows consistent selling that investors may interpret as a lack of incremental bullish conviction by the holder. Without earnings or operational disclosures, the filing is neutral from a fundamentals standpoint but may exert slight short-term sentiment pressure.

Corporate Governance Expert

TL;DR: Routine Rule 144 filing; transparency positive, but repeated insider sales can raise governance questions.

Rule 144 filings foster disclosure discipline, and the signer affirms no possession of undisclosed negative information. Yet, regular block sales—totaling 77,000 shares including the new notice—could trigger investor queries on management’s alignment, especially if Mahon is a senior affiliate. Because the aggregate sales remain under 0.2 % of shares outstanding, I classify the governance impact as modestly negative but not material.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	11000	3303393.50	45106623	07/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/10/2025	Stock Option Exercise	Issuer			11000	07/10/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	06/26/2025	11000	3142717.60
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	06/12/2025	11000	3079513.80
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/29/2025	4000	1263080.00
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/29/2025	7000	2213684.90
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/15/2025	11000	3246149.50
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/01/2025	11000	3310200.30
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	04/17/2025	11000	3121542.60

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many UTHR shares are proposed for sale in the latest Form 144?

The filing covers 11,000 common shares, valued at approximately $3.30 million.

What percentage of United Therapeutics’ outstanding shares does 11,000 shares represent?

With 45.11 million shares outstanding, the proposed sale equals about 0.024 % of total shares.

How many shares has the filer sold in the last three months?

Prior Rule 144 reports list 66,000 shares sold between 04/17/2025 and 06/26/2025.

What were the gross proceeds from the past three months of UTHR share sales?

The seven transactions generated roughly $19.38 million in total gross proceeds.

Does a Form 144 guarantee that the insider will sell the shares?

No. It only signals intent; the shares may or may not be sold, depending on market conditions and compliance windows.